Gene Recombinant Protein-Based Therapy "CNT201"
"Submitting Cellulite Indication Clinical Trial IND to the FDA This Year"

Konext is joining hands with Pharmaresearch to commercialize a recombinant protein-based cellulite treatment.

From left: Son Jihoon, CEO of Pharmaresearch, and Lee Woojong, CEO of Conext. Korea Bio Association

From left: Son Jihoon, CEO of Pharmaresearch, and Lee Woojong, CEO of Conext. Korea Bio Association

View original image

Konext and Pharmaresearch announced on February 23 that they have signed a licensing and supply agreement for the recombinant protein therapy “CNT201.” Under the agreement, Konext will be responsible for clinical development and manufacturing, while Pharmaresearch will handle development for aesthetic indications and global commercialization.


CNT201 is a recombinant protein therapy that targets diseases involving abnormalities in collagen fiber tissue. It is being developed for indications such as Dupuytren's contracture, Peyronie's disease, and cellulite. According to the companies, a key differentiating factor is that it is a recombinant protein-based therapy that does not use any animal-derived components. Konext is preparing to list on the KOSDAQ market with CNT201 as its core asset.


The indication for Dupuytren's contracture is currently in Phase 2 clinical trials after receiving Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA). For the cellulite indication, the company plans to submit an IND application to the FDA within this year and push ahead with entry into Phase 2 trials. The company has set a target of advancing both indications into Phase 3 trials by 2028. Although cellulite is an area with strong aesthetic demand, injectable treatment options remain limited.


Under this agreement, Konext will lead the clinical strategy while maintaining its pipeline development and manufacturing capabilities. Pharmaresearch will work to enter global markets based on its clinical network and commercialization experience in the aesthetics field.



Konext plans to submit an IND application to the FDA this year for the cellulite indication and initiate a Phase 2 clinical trial. The company is targeting 2028 for the start of Phase 3 clinical trials for both the Dupuytren's contracture and cellulite indications.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing